Abstract
The development of several different chemical modifications of nucleic acids, with improved base-pairing affinity and specificity as well as increased resistance against nucleases, has been described. These new chemistries have allowed the synthesis of different types of therapeutic oligonucleotides. Here we discuss selected chemistries used in antisense oligonucleotide (ASO) applications (e.g., small interfering RNA (siRNA), RNase H activation, translational block, splice-switching, and also as aptamers). Recently approved oligonucleotide-based drugs are also presented briefly.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Reist EJ, Benitez A, Goodman L (1964) The synthesis of some 5′-thiopentofuranosylpyrimidines. J Org Chem 29(3):554–558
Codington JF, Doerr IL, Fox JJ (1964) Nucleosides. XVIII. Synthesis of 2′-fluorothymidine, 2′-fluorodeoxyuridine, and other 2′-halogeno-2′-deoxy nucleosides. J Org Chem 29(3):558–564
Eckstein F (1966) Nucleoside phosphorothioates. J Am Chem Soc 88:4292–4294
Bobst AM, Rottman F, Cerutti PA (1969) Effect of the methylation of the 2′-hydroxyl groups in polyadenylic acid on its structure in weakly acidic and neutral solutions and on its capability to form ordered complexes with polyuridylic acid. J Mol Biol 46(2):221–234
Martin P (1995) Ein neuer zugang zu 2′-O-alkylribonucleosiden und eigenschaften deren oligonucleotide. Helv Chim Acta 78(2):486–504
Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7(3):187–195
Nielsen PE, Egholm M, Berg RH, Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254(5037):1497–1500
Nielsen P, Dreioe LH, Wengel J (1995) Synthesis and evaluation of oligodeoxynucleotides containing acyclic nucleosides: introduction of three novel analogues and a summary. Bioorg Med Chem 3(1):19–28
Obika S, Nanbu D, Hari Y, Morio K-I, In Y, Ishida T et al (1997) Synthesis of 2′-O, 4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett 38:8735–8738
Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M et al (1998) Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54:3607–3630
Seth PP, Siwkowski A, Allerson CR, Vasquez G, Lee S, Prakash TP et al (2009) Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52(1):10–13
Renneberg D, Leumann CJ (2002) Watson-crick base-pairing properties of tricyclo-DNA. J Am Chem Soc 124(21):5993–6002
Lundin KE, Gissberg O, Smith CI (2015) Oligonucleotide therapies: the past and the present. Hum Gene Ther 26(8):475–485
Smith CIE, Zain R (2019) Therapeutic oligonucleotides: state of the art. Annu Rev Pharmacol Toxicol 59:605–630
Terrazas M, Kool ET (2009) RNA major groove modifications improve si RNA stability and biological activity. Nucleic Acids Res 37(2):346–353
Ostergaard ME, Kumar P, Nichols J, Watt A, Sharma PK, Nielsen P et al (2015) Allele-selective inhibition of mutant huntingtin with 2-thio- and C5- triazolylphenyl-deoxythymidine-modified antisense oligonucleotides. Nucleic Acid Ther. 25(5):266–274
Wan WB, Seth PP (2016) The medicinal chemistry of therapeutic oligonucleotides. J Med Chem 59(21):9645–9667
Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 292(2):468–479
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC et al (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719):998–1006
Gidaro T, Servais L (2019) Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol 61(1):19–24
Lundin KE, Hojland T, Hansen BR, Persson R, Bramsen JB, Kjems J et al (2013) Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet 82:47–107
Lou C, Samuelsen SV, Christensen NJ, Vester B, Wengel J (2017) Oligonucleotides containing aminated 2′-amino-LNA nucleotides: synthesis and strong binding to complementary DNA and RNA. Bioconjug Chem 28(4):1214–1220
Lee T, Awano H, Yagi M, Matsumoto M, Watanabe N, Goda R et al (2017) 2′-O-methyl RNA/ethylene-bridged nucleic acid chimera antisense oligonucleotides to induce dystrophin exon 45 skipping. Genes (Basel) 8(2)
Iribe H, Miyamoto K, Takahashi T, Kobayashi Y, Leo J, Aida M et al (2017) Chemical modification of the si RNA seed region suppresses off-target effects by steric hindrance to base-pairing with targets. ACS Omega 2(5):2055–2064
Mook O, Vreijling J, Wengel SL, Wengel J, Zhou C, Chattopadhyaya J et al (2010) In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified si RNA and small internally segmented interfering RNA (sisi RNA) in mice bearing human tumor xenografts. Artif DNA PNA XNA 1(1):36–44
Kotkowiak W, Lisowiec-Wachnicka J, Grynda J, Kierzek R, Wengel J, Pasternak A (2018) Thermodynamic, anticoagulant, and Antiproliferative properties of thrombin binding aptamer containing novel UNA derivative. Mol Ther Nucleic Acids. 10:304–316
Ferino A, Miglietta G, Picco R, Vogel S, Wengel J, Xodo LE (2018) Micro RNA therapeutics: design of single-stranded mi R-216b mimics to target KRAS in pancreatic cancer cells. RNA Biol 15(10):1273–1285
Heidenreich O, Gryaznov S, Nerenberg M (1997) RNase H-independent antisense activity of oligonucleotide N3′--> P 5′ phosphoramidates. Nucleic Acids Res 25(4):776–780
Schrank Z, Khan N, Osude C, Singh S, Miller RJ, Merrick C et al (2018) Oligonucleotides targeting telomeres and telomerase in cancer. Molecules 23(9)
Eckstein F (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acids Ther 24(6):374–387
Iannitti T, Morales-Medina JC, Palmieri B (2014) Phosphorothioate oligonucleotides: effectiveness and toxicity. Curr Drug Targets 15(7):663–673
Henry SP, Seguin R, Cavagnaro J, Berman C, Tepper J, Kornbrust D (2016) Considerations for the characterization and interpretation of results related to alternative complement activation in monkeys associated with oligonucleotide-based therapeutics. Nucleic Acids Ther 26(4):210–215
Narayanan P, Shen L, Curtis BR, Bourdon MA, Nolan JP, Gupta S et al (2018) Investigation into the mechanism (s) that leads to platelet decreases in cynomolgus monkeys during administration of ISIS 104838, a 2′-MOE-modified antisense oligonucleotide. Toxicol Sci 164(2):613–626
Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N et al (2017) The effects of 2′-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acids Ther 27(3):121–129
Stirchak EP, Summerton JE, Weller DD (1989) Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res 17(15):6129–6141
Yokota T, Duddy W, Partridge T (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26(3):179–184
Du L, Gatti RA (2011) Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases. J Immunol Methods 365(1–2):1–7
Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, Moulton HM et al (2005) Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 79(8):4599–4609
Nan Y, Zhang YJ (2018) Antisense Phosphorodiamidate Morpholino oligomers as novel antiviral compounds. Front Microbiol 9:750
Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533–545
Bestas B, Moreno PM, Blomberg KE, Mohammad DK, Saleh AF, Sutlu T et al (2014) Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. J Clin Invest 124(9):4067–4081
Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN et al (2016) Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A 113(39):10962–10967
Lundin KE, Good L, Stromberg R, Graslund A, Smith CI (2006) Biological activity and biotechnological aspects of peptide nucleic acid. Adv Genet 56:1–51
Gupta A, Mishra A, Puri N (2017) Peptide nucleic acids: advanced tools for biomedical applications. J Biotechnol 259:148–159
Narenji H, Gholizadeh P, Aghazadeh M, Rezaee MA, Asgharzadeh M, Kafil HS (2017) Peptide nucleic acids (PNAs): currently potential bactericidal agents. Biomed Pharmacother 93:580–588
Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM et al (2012) Nanoparticle-based therapy in an in vivo micro RNA-155 (mi R-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 109(26):E1695–E1704
Brognara E, Fabbri E, Aimi F, Manicardi A, Bianchi N, Finotti A et al (2012) Peptide nucleic acids targeting mi R-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int J Oncol 41(6):2119–2127
Montazersaheb S, Hejazi MS, Nozad CH (2018) Potential of peptide nucleic acids in future therapeutic applications. Adv Pharm Bull 8(4):551–563
Murray S, Ittig D, Koller E, Berdeja A, Chappell A, Prakash TP et al (2012) Tricyclo DNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res 40(13):6135–6143
Relizani K, Goyenvalle A (2018) Use of Tricyclo-DNA antisense oligonucleotides for exon skipping. Methods Mol Biol 1828:381–394
Ivanova G, Reigadas S, Ittig D, Arzumanov A, Andreola ML, Leumann C et al (2007) Tricyclo-DNA containing oligonucleotides as steric block inhibitors of human immunodeficiency virus type 1 tat-dependent trans-activation and HIV-1 infectivity. Oligonucleotides 17(1):54–65
Robin V, Griffith G, Carter JL, Leumann CJ, Garcia L, Goyenvalle A (2017) Efficient SMN rescue following subcutaneous Tricyclo-DNA antisense oligonucleotide treatment. Mol Ther Nucleic Acids 7:81–89
Aupy P, Echevarria L, Relizani K, Goyenvalle A (2017) The use of Tricyclo-DNA oligomers for the treatment of genetic disorders. Biomedicine 6(1)
Geary RS, Henry SP, Grillone LR (2002) Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 41(4):255–260
Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF (1996) Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 40(9):2004–2011
Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5(2):123–132
Geary RS, Baker BF, Crooke ST (2015) Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro((R))): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet 54(2):133–146
Yu RZ, Grundy JS, Henry SP, Kim TW, Norris DA, Burkey J et al (2015) Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2′-o-(2-methoxyethyl) modifications. Mol Ther Nucleic Acids 4:e218
Sazani P, Ness KP, Weller DL, Poage DW, Palyada K, Shrewsbury SB (2011) Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy. Int J Toxicol 30(3):313–321
Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF et al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24(15):1634–1644
Yang J (2019) Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol 12(2):95–99
Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584–1600
Rodrigues M, Yokota T (2018) An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases. Methods Mol Biol 1828:31–55
Khvorova A (2017) Oligonucleotide therapeutics – a new class of cholesterol-lowering drugs. N Engl J Med 376(1):4–7
Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR et al (2017) Clinical proof of concept for a novel hepatocyte-targeting gal NAc-si RNA conjugate. Mol Ther 25(1):71–78
Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, Gryaznov SM et al (2007) Antiadhesive effects of GRN163L – an oligonucleotide N3′->P 5′ thio-phosphoramidate targeting telomerase. Cancer Res 67(3):1121–1129
Hamel Y, Lacoste J, Frayssinet C, Sarasin A, Garestier T, Francois JC et al (1999) Inhibition of gene expression by anti-sense C-5 propyne oligonucleotides detected by a reporter enzyme. Biochem J 339(Pt 3):547–553
Wagner RW, Matteucci MD, Grant D, Huang T, Froehler BC (1996) Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat Biotechnol 14(7):840–844
Kamiya Y, Donoshita Y, Kamimoto H, Murayama K, Ariyoshi J, Asanuma H (2017) Introduction of 2,6-diaminopurines into Serinol nucleic acid improves anti-mi RNA performance. Chembiochem 18(19):1917–1922
Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ et al (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268(19):14514–14522
Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald CM et al (2018) A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord 28(1):4–15
Maruyama R, Touznik A, Yokota T (2018) Evaluation of exon inclusion induced by splice switching antisense oligonucleotides in SMA patient fibroblasts. J Vis Exp 135
Lima JF, Carvalho J, Pinto-Ribeiro I, Almeida C, Wengel J, Cerqueira L et al (2018) Targeting mi R-9 in gastric cancer cells using locked nucleic acid oligonucleotides. BMC Mol Biol 19(1):6
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al (2005) Silencing of micro RNAs in vivo with ‘antagomirs’. Nature 438(7068):685–689
Nulf CJ, Corey D (2004) Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Res 32(13):3792–3798
Edwards SL, Poongavanam V, Kanwar JR, Roy K, Hillman KM, Prasad N et al (2015) Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition. Chem Commun (Camb) 51(46):9499–9502
Elle IC, Karlsen KK, Terp MG, Larsen N, Nielsen R, Derbyshire N et al (2015) Selection of LNA-containing DNA aptamers against recombinant human CD73. Mol BioSyst 11(5):1260–1270
Volk DE, Lokesh GLR (2017) Development of phosphorothioate DNA and DNA thioaptamers. Biomedicine 5(3)
Faria M, Spiller DG, Dubertret C, Nelson JS, White MR, Scherman D et al (2001) Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat Biotechnol 19(1):40–44
Gryaznov SM (2010) Oligonucleotide n3′-->p 5′ phosphoramidates and thio-phoshoramidates as potential therapeutic agents. Chem Biodivers 7(3):477–493
Gao X, Shen X, Dong X, Ran N, Han G, Cao L et al (2015) Peptide nucleic acid promotes systemic dystrophin expression and functional rescue in dystrophin-deficient mdx mice. Mol Ther Nucleic Acids 4:e255
Siwkowski AM, Malik L, Esau CC, Maier MA, Wancewicz EV, Albertshofer K et al (2004) Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res 32(9):2695–2706
Doyle DF, Braasch DA, Simmons CG, Janowski BA, Corey DR (2001) Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length. Biochemistry 40(1):53–64
Acknowledgments
This work was supported by the Swedish Research Council, the Stockholm County Council, Hjärnfonden, and Vinnova/SweLife.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Lundin, K.E., Gissberg, O., Smith, C.I.E., Zain, R. (2019). Chemical Development of Therapeutic Oligonucleotides. In: Gissberg, O., Zain, R., Lundin, K. (eds) Oligonucleotide-Based Therapies. Methods in Molecular Biology, vol 2036. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9670-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9670-4_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9669-8
Online ISBN: 978-1-4939-9670-4
eBook Packages: Springer Protocols